Upgrade to SI Premium - Free Trial

JPMorgan Downgrades Intellia Therapeutics (NTLA) to Neutral

February 28, 2025 2:12 AM
JPMorgan analyst Brian Cheng downgraded Intellia Therapeutics (NASDAQ: NTLA) from Overweight to Neutral with a price target of $13.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades

Next Articles